Investing IdeasBrowse All StocksMarkets

Have your own idea? Try our Stock Screener

Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedDec 30, 2024
DataAggregated Company Financials
Companies7
  • 7D1.9%
  • 3M-5.4%
  • 1Y5.2%
  • YTD3.5%

In the last week, the Pharma industry is up 2.4%, with all of the companies up. This takes the industry's 12 month performance to a gain of 5.2%. Looking forward, earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 30 Dec 2024CHF 425.4bCHF 119.2bCHF 21.4b17.9x19.9x3.6x
Wed, 27 Nov 2024CHF 428.5bCHF 118.2bCHF 21.2b18.2x20.2x3.6x
Fri, 25 Oct 2024CHF 464.1bCHF 115.9bCHF 19.5b21.9x23.8x4x
Sun, 22 Sep 2024CHF 456.3bCHF 114.9bCHF 19.3b21.8x23.6x4x
Tue, 20 Aug 2024CHF 470.8bCHF 115.7bCHF 19.4b22.3x24.2x4.1x
Thu, 18 Jul 2024CHF 460.2bCHF 115.5bCHF 19.6b34.5x23.4x4x
Sat, 15 Jun 2024CHF 430.3bCHF 115.9bCHF 19.7b33.8x21.8x3.7x
Mon, 13 May 2024CHF 405.5bCHF 113.2bCHF 19.9b40.9x20.4x3.6x
Wed, 10 Apr 2024CHF 398.1bCHF 112.0bCHF 19.4b36.5x20.5x3.6x
Fri, 08 Mar 2024CHF 387.3bCHF 110.2bCHF 19.7b23.9x19.7x3.5x
Sun, 04 Feb 2024CHF 399.2bCHF 114.1bCHF 19.2b30.3x20.8x3.5x
Tue, 02 Jan 2024CHF 394.8bCHF 118.7bCHF 18.6b25.4x21.3x3.3x
Thu, 30 Nov 2023CHF 387.2bCHF 120.9bCHF 18.9b24.4x20.5x3.2x
Sat, 28 Oct 2023CHF 385.3bCHF 122.6bCHF 19.1b23.4x20.2x3.1x
Mon, 25 Sep 2023CHF 402.8bCHF 113.2bCHF 18.1b45.4x22.2x3.6x
Wed, 23 Aug 2023CHF 403.1bCHF 111.8bCHF 17.9b48x22.5x3.6x
Fri, 21 Jul 2023CHF 420.6bCHF 114.4bCHF 19.2b37x21.9x3.7x
Sun, 18 Jun 2023CHF 428.0bCHF 115.0bCHF 18.9b38.1x22.7x3.7x
Tue, 16 May 2023CHF 436.0bCHF 115.1bCHF 18.9b40.5x23.1x3.8x
Thu, 13 Apr 2023CHF 431.0bCHF 114.8bCHF 18.8b42x22.9x3.8x
Sat, 11 Mar 2023CHF 382.4bCHF 116.1bCHF 19.0b26.1x20.1x3.3x
Mon, 06 Feb 2023CHF 429.0bCHF 117.9bCHF 21.3b28.7x20.2x3.6x
Wed, 04 Jan 2023CHF 439.1bCHF 117.8bCHF 34.9b22.7x12.6x3.7x
Fri, 02 Dec 2022CHF 448.3bCHF 117.8bCHF 34.9b23.5x12.8x3.8x
Sun, 30 Oct 2022CHF 458.0bCHF 120.9bCHF 36.2b22.3x12.7x3.8x
Tue, 27 Sep 2022CHF 424.9bCHF 121.1bCHF 37.3b19.7x11.4x3.5x
Thu, 25 Aug 2022CHF 449.8bCHF 119.8bCHF 36.7b21.3x12.3x3.8x
Sat, 23 Jul 2022CHF 461.8bCHF 118.9bCHF 36.4b28x12.7x3.9x
Mon, 20 Jun 2022CHF 430.9bCHF 119.2bCHF 37.6b25.1x11.5x3.6x
Wed, 18 May 2022CHF 467.8bCHF 120.3bCHF 38.1b28.6x12.3x3.9x
Fri, 15 Apr 2022CHF 524.1bCHF 117.5bCHF 36.7b33.9x14.3x4.5x
Sun, 13 Mar 2022CHF 470.3bCHF 117.1bCHF 36.5b20.2x12.9x4x
Tue, 08 Feb 2022CHF 470.1bCHF 116.5bCHF 36.3b19.8x13x4x
Thu, 06 Jan 2022CHF 492.5bCHF 111.9bCHF 23.2b21.4x21.3x4.4x
Price to Earnings Ratio

21.3x


Total Market Cap: CHF 492.5bTotal Earnings: CHF 23.2bTotal Revenue: CHF 111.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 18.7x20232024
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 18.7x.
  • The industry is trading close to its 3-year average PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 2.7% per year over the last three years.
  • Meanwhile revenues for these companies have grown 2.1% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.11%
Healthcare1.68%
Pharma1.89%
Pharma1.89%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROG Roche HoldingCHF 255.501.8%
+CHF 3.6b		4.5%PE19.2x
NOVN NovartisCHF 88.701.2%
+CHF 2.0b		4.5%PE16.6x
GALD Galderma GroupCHF 100.642.3%
+CHF 544.0m		n/aPS6.1x
DESN Dottikon ES HoldingCHF 221.002.1%
+CHF 62.2m		-3.5%PE40.4x
SDZ Sandoz GroupCHF 37.170.3%
+CHF 48.3m		37.4%PS1.8x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlans & PricingLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

NOVN

CHF 88.70

Novartis

7D

1.2%

1Y

4.5%

DESN

CHF 221.00

Dottikon ES Holding

7D

2.1%

1Y

-3.5%

These 4 Measures Indicate That Dottikon ES Holding (VTX:DESN) Is Using Debt Extensively

Dec 29
These 4 Measures Indicate That Dottikon ES Holding (VTX:DESN) Is Using Debt Extensively

GALD

CHF 100.64

Galderma Group

7D

2.3%

1Y

n/a

Is There An Opportunity With Galderma Group AG's (VTX:GALD) 50% Undervaluation?

Dec 18
Is There An Opportunity With Galderma Group AG's (VTX:GALD) 50% Undervaluation?

ROG

CHF 255.50

Roche Holding

7D

1.8%

1Y

4.5%

NWRN

CHF 8.95

Newron Pharmaceuticals

7D

5.4%

1Y

80.8%

COPN

CHF 63.70

Cosmo Pharmaceuticals

7D

4.1%

1Y

25.1%

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable

Nov 22
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable

CURN

CHF 13.00

Curatis Holding

7D

2.4%

1Y

n/a

SDZ

CHF 37.17

Sandoz Group

7D

0.3%

1Y

37.4%